ProCE Banner Events


Advances in the Management of Metastatic Castration-Resistant Prostate Cancer: Expert Guidance and Resources for the Interdisciplinary Team: An NCCN/CCO Meeting Series [Open Registration]

Register now for this CME/CNE/CPE/AAPA-certified interactive workshop series on the latest advances in the management of metastatic castration-resistance prostate cancer! After the meeting, download the associated slideset on optimal management of mCRPC.

To Register: Please click the green “Learn More” button below. On the next page, select Register for Virtual Event. Once registered, you will receive a confirmation email. Follow-up emails with event details will be sent as the event nears.

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Credits Available


Who Should Attend

This educational program is intended for oncology physicians, nurses, nurse practitioners, pharmacists, physician associates, and other healthcare professionals who care for patients with prostate cancer.

Time and location

Wednesday, March 13, 2024

4:30 PM - 5:30 PM Central Time (CT)


CCO Simulcast | Host Group OK
Norman, Oklahoma

Xin Gao, MD

Assistant Professor of Medicine
Harvard Medical School
Medical Oncologist
Massachusetts General Hospital
Boston, Massachusetts


  • Welcome and Introduction
  • Case Discussions: Applying the Evidence to Practice
  • Partners in Patient-Centered Care
  • Advances and Future Directions for Patients With mCRPC
  • Putting It All Together: Takeaway Resources and Discussion of Available Online Resources and Tools
  • Audience Question and Answer


Venue Name

CCO Simulcast | Host Group OK


CCO Simulcast | Host Group OK
Norman, Oklahoma


The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with metastatic castration-resistant prostate cancer.

Target Audience
This educational program is intended for oncology physicians, nurses, nurse practitioners, pharmacists, physician associates, and other healthcare professionals who care for patients with prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Select optimal evidence-based treatment and supportive care options for patients with newly diagnosed mCRPC, mCRPC with HRR gene alterations, and recurrent mCRPC
  • Counsel patients and caregivers on unique toxicities associated with targeted therapies used to treat mCRPC and provide guidance on AE management
  • Develop a proactive management plan to support adherence in patients with prostate cancer receiving oral therapies, including identifying potential adherence barriers and implementing strategies to overcome them
  • Identify all patients with prostate cancer who may be eligible to ensure equitable enrollment in ongoing clinical studies investigating novel regimens, considering potential racial, age, and socioeconomic disparities



Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

NCCN designates this educational activity for a maximum of 1.0 contact hour.

Continuing Pharmacy Education

NCCN designates this application-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-23-102-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate/Physician Assistant Continuing Medical Education

LogoDescription automatically generated

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose all financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships. In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. Full disclosure of faculty relationships will be made prior to the activity.


Provided by the National Comprehensive Cancer Network (NCCN) in partnership with Clinical Care Options, LLC

This activity is supported by educational grants from AstraZeneca and Novartis Pharmaceuticals Corp. This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.